Skip to main content

Access to Tirzepatide (Mounjaro®) for Weight Management in the Black Country

From 23 June 2025, access to the medication tirzepatide (Mounjaro®) is beginning in England for a small number of patients living with obesity who are at the highest risk of serious health conditions.

In the Black Country, new community-based weight management services are currently being developed to support safe and effective access to this treatment, this means GPs are not yet able to prescribe tirzepatide (Mounjaro®) for weight management in this area.

We’re working quickly to make these services available. As part of our phased approach, the first group of patients who may be eligible will include those who:

  • Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds),
  • And have obstructive sleep apnoea on CPAP (or where CPAP is not suitable or tolerated),
  • And have at least three of the following long-term conditions:
    • Type 2 diabetes
    • High blood pressure (hypertension)
    • Cardiovascular disease
    • Dyslipidaemia

Other patients who meet the broader NHS criteria (BMI ≥ 40 and four or more related health conditions) may become eligible in later stages.

Please do not contact your GP about tirzepatide at this time. GPs currently cannot prescribe this treatment or refer patients into the new pathway until local services are launched.

Access to tirzepatide will be alongside structured diet, exercise and behavioural support to ensure patients are supported in achieving and maintaining a healthy weight.

We will update this page regularly and share information with local partners as soon as the new service becomes available.

Thank you for your patience as we work to introduce this important new treatment safely and fairly.

Please note:

Black Country ICB supports a practice’s decision to continue prescribing for a medicine that was initiated prior to the publication of the NICE Technology Appraisal (TA1026) 23rd December 2024, provided it meets the usual prescribing criteria requirements.

Tirzepatide for the management of type 2 diabetes is not part of this weight management pathway and is already prescribable as per Black Country ICB formulary website.